New Ru(II)-p-cymene compounds bearing indomethacin and indomethacin-pyridineamide ligands: synthesis, characterization, computational studies and investigation of their interactions with the Human Serum Albumin

Abstract

The research interest in ruthenium(II) organometallic compounds has continually increased due to their promising performance in biological assays targeting diverse medicinal applications. This work reports the interactions of the [Ru(II)-η6-p-cymene] framework with the indomethacin (HL1) drug and with its modified analogue indomethacin-pyridineamide (L2). Two new half-sandwich organometallics, [Ru(η6-p-cymene)(L1)Cl] (1) and [Ru(η6-p-cymene)(L2)Cl2] (2), were successfully synthesized and fully characterized by ESI-MS, NMR, ATR-FTIR and UV/VIS spectroscopy. The chemical and electronic structures were corroborated by DFT computational calculations. Compound 2 was chemically stable, keeping the L2 ligand in the coordination sphere in coordinating solvents, and was investigated for the interaction with the Human Serum Albumin (HSA) protein by fluorescence quenching studies. This compound acted as a quencher to the intrinsic protein fluorescence, mainly through binding-related quenching (static) mechanism, showing high value for the apparent association constant (Ka). The analysis of the thermodynamic parameters revealed spontaneous process, presenting low temperature dependence, with electrostatic forces playing a key role in the HSA-compound 2 adduct binding. Site competitive studies suggested that the organometallic 2 may compete for the binding site of ibuprofen (subdomain IIIA) and also for the binding site of Ru(III) naked ion (subdomain IB or IIA). Molecular docking simulations showed that both Ru(II)-arenes may interact through hydrogen bonding with arginine residues, and exhibit high affinity for the microenvironment located in subdomains IIIA and IB. These findings suggest that the HSA protein might be a potential carrier for these Ru(II)-organometallic compounds in the blood plasma.